Anna Edney
Senate Republicans’ health bill would leave 22 million more uninsured
Updated at 4:46 p.m.
NEW YORK - The Obamacare replacement plan put forward by Senate Republicans would increase the number of uninsured Americans by 22...
Senate Republicans brace for release of health bill Thursday
NEW YORK - Senate Republicans are beginning to learn the details of the health care bill they may be asked to vote on next...
Drug prices become target for FDA as chief expands purview
NEW YORK - The head of the U.S. Food and Drug Administration is considering using the agency’s powers to bring more price competition to...
CBO: GOP health plan will cut deficit by $119B, cause 23M...
NEW YORK - Republicans’ revised plan to repeal and replace parts of the Affordable Care Act would shrink the U.S. budget deficit by $119...
Trump threats on Obamacare funds may push out poor, insurers
NEW YORK - As Congress wrangles over how to gut Obamacare in the coming years, a move threatened by the Trump administration could weaken...
House passes Obamacare repeal in razor-thin Republican victory
WASHINGTON - House Republicans mustered just enough votes to pass their health-care bill Thursday, salvaging what at times appeared to be a doomed mission...
GOP health plan to boost uninsured by 14M in a year,...
WASHINGTON - About 24 million more people would be uninsured under the Republican plan to replace Obamacare, according to the nonpartisan Congressional Budget Office,...
Republicans unveil health care bill to bridge gaps in party
WASHINGTON - Republicans unveiled their long-awaited legislation to repeal and replace the Affordable Care Act, proposing to phase out key parts of the law...
Alexion skids as muscle drug trial fails to meet primary goal
WASHINGTON - Alexion Pharmaceuticals Inc. fell the most in six years after the company’s drug for a rare neuromuscular disease failed to meet its...
Amgen’s first-of-its-kind skin cancer drug wins U.S. approval
SAN FRANCISCO - Amgen Inc.’s therapy for a deadly form of skin cancer was approved by U.S. regulators, letting the drugmaker move forward even...